We are live on ! Find out more
MBRX icon

Moleculin Biotech
MBRX

9 hedge funds and large institutions have $1.1M invested in Moleculin Biotech in 2024 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 0 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

9,354% more capital inflows, than outflows

Capital inflows: $261K | Capital outflows: $2.76K

1.99% more ownership

Funds ownership: 11.59% → 13.58% (+2%)

0% more funds holding

Funds holding: 9 → 9 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

Holders
9
Holders Change
–
Holders Change %
0%
% of All Funds
0.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
5
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
LPL Financial
LPL Financial
California
+$157K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$41.6K
3
Armistice Capital
Armistice Capital
New York
+$34.6K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$16.2K
5
Tower Research Capital (TRC)
Tower Research Capital (TRC)
New York
+$6.93K

Top Sellers

Rank Fund Capital Flow
1
FIM
FWL Investment Management
Texas
-$1.64K
2
NBC Securities
NBC Securities
Alabama
-$1K
3
Wells Fargo
Wells Fargo
California
-$112
4
NewEdge Advisors
NewEdge Advisors
Louisiana
-$6

MBRX Hedge Fund Activity: Q2 2024 in Review

9 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q2 2024, worth a combined $1.1M — down 28% from $1.53M a quarter earlier.

Fund positioning in MBRX was balanced in Q2 2024: 1 fund opened new positions, 1 closed out, 5 added to existing stakes and 0 trimmed.

The largest buyer was LPL Financial, opening a new position worth an estimated $157K. The largest seller was FWL Investment Management, exiting entirely with an estimated $1.64K sold.

  • 9 institutional investors held Moleculin Biotech (MBRX) as of Q2 2024, unchanged from Q1 2024.
  • Funds reported $1.1M of Moleculin Biotech stock for Q2 2024, down 28% quarter-over-quarter.
  • 1 fund opened new Moleculin Biotech positions in Q2 2024 and 1 closed out, a net change of 0 holders.
  • The largest Moleculin Biotech buyer in Q2 2024 was LPL Financial, an estimated $157K added.
  • The largest Moleculin Biotech seller in Q2 2024 was FWL Investment Management, an estimated $1.64K sold.

Based on aggregated 13F filings for Q2 2024.